{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:59:20Z","timestamp":1775325560274,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The short\u2010term effectiveness of tolvaptan (TLV) against heart failure has been established. TLV is known to decrease the worsening of renal function more than loop diuretics. Long\u2010term TLV administration decreases the rate of re\u2010hospitalization in heart failure and prevents deterioration of kidney function. If repeated hospitalization for heart failure can be prevented in patients having concurrent chronic kidney disease (CKD), the period until dialysis initiation may be prolonged. We investigated whether long\u2010term TLV management can extend the period until dialysis initiation in patients with CKD and heart failure. A retrospective, observational study was conducted among patients with CKD stage G4 and G5 admitted because of heart failure between April 2013 and July 2018. They were divided into those with TLV and those without TLV. They were followed up until August 2018 and relevant data was collected. Data from 115 patients (68 men and 47 women), with a mean age of 73.4\u2009\u00b1\u200911.9 (median 76.0 and IQR 66.5\u201382.0) years and a mean eGFR of 11.8\u2009\u00b1\u20095.7 (median 9.9 and IQR 7.5\u201314.8) mL\/min\/1.73m\n                    <jats:sup>2<\/jats:sup>\n                    were included in the analysis. Twenty\u2010five patients had received long\u2010term TLV treatment, and 90 had not. Multivariate analysis after adjustment showed that long\u2010term use of TLV significantly lowered the hazard ratio (HR) for time taken to reach dialysis initiation (HR: 0.3286, 95%CI: 0.1282\u20130.8423,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0205). Propensity score\u2010matched analysis showed similar results (HR: 0.3220, 95%CI: 0.1107\u20130.9369,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0376). In patients with CKD G4 and G5 and heart failure, long\u2010term treatment with TLV can prolong the time until dialysis initiation.\n                  <\/jats:p>","DOI":"10.1111\/1744-9987.12789","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T02:43:29Z","timestamp":1545273809000},"page":"319-327","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Long\u2010Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-5901","authenticated-orcid":false,"given":"Akihito","family":"Tanaka","sequence":"first","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Ito","sequence":"additional","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibiki","family":"Shinjo","sequence":"additional","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Takeda","sequence":"additional","affiliation":[{"name":"Kidney Disease Center Japanese Red Cross Nagoya Daini Hospital Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC\u201041061, a highly potent human vasopressin V2\u2010receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura Y","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","article-title":"Effects of the V(2)\u2010receptor antagonist OPC\u201041061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano T","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4082"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.16.1963"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2005.03.009"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2016.02.007"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/AC.70.2.3073514"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e328355a740"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-015-0775-9"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-17-0554"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2012.08.020"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-016-0872-4"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.01.416"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197112232852601"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.192"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0022-3565(25)20166-5","article-title":"Intratubular albumin blunts the response to furosemide\u2010a mechanism for diuretic resistance in the nephrotic syndrome","volume":"252","author":"Kirchner KA","year":"1990","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1744-9987.12789","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T17:11:09Z","timestamp":1775322669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/1744-9987.12789"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12789","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"2018-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}